OMGA vs. KPTI, SGMO, CMRX, IVA, PSNL, TCRX, TRML, FATE, EDIT, and KYTX
Should you be buying Omega Therapeutics stock or one of its competitors? The main competitors of Omega Therapeutics include Karyopharm Therapeutics (KPTI), Sangamo Therapeutics (SGMO), Chimerix (CMRX), Inventiva (IVA), Personalis (PSNL), TScan Therapeutics (TCRX), Tourmaline Bio (TRML), Fate Therapeutics (FATE), Editas Medicine (EDIT), and Kyverna Therapeutics (KYTX). These companies are all part of the "medical" sector.
Karyopharm Therapeutics (NASDAQ:KPTI) and Omega Therapeutics (NASDAQ:OMGA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability, community ranking, valuation and media sentiment.
Karyopharm Therapeutics has a beta of 0.25, indicating that its share price is 75% less volatile than the S&P 500. Comparatively, Omega Therapeutics has a beta of 1.91, indicating that its share price is 91% more volatile than the S&P 500.
Omega Therapeutics has lower revenue, but higher earnings than Karyopharm Therapeutics. Omega Therapeutics is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.
Karyopharm Therapeutics presently has a consensus target price of $4.80, indicating a potential upside of 395.87%. Omega Therapeutics has a consensus target price of $10.00, indicating a potential upside of 412.82%. Given Karyopharm Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Omega Therapeutics is more favorable than Karyopharm Therapeutics.
In the previous week, Karyopharm Therapeutics had 2 more articles in the media than Omega Therapeutics. MarketBeat recorded 3 mentions for Karyopharm Therapeutics and 1 mentions for Omega Therapeutics. Karyopharm Therapeutics' average media sentiment score of 0.94 beat Omega Therapeutics' score of 0.70 indicating that Omega Therapeutics is being referred to more favorably in the news media.
Karyopharm Therapeutics received 504 more outperform votes than Omega Therapeutics when rated by MarketBeat users. Likewise, 72.09% of users gave Karyopharm Therapeutics an outperform vote while only 71.88% of users gave Omega Therapeutics an outperform vote.
66.4% of Karyopharm Therapeutics shares are owned by institutional investors. Comparatively, 97.5% of Omega Therapeutics shares are owned by institutional investors. 4.3% of Karyopharm Therapeutics shares are owned by insiders. Comparatively, 57.0% of Omega Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Karyopharm Therapeutics has a net margin of -104.18% compared to Karyopharm Therapeutics' net margin of -1,868.35%. Omega Therapeutics' return on equity of 0.00% beat Karyopharm Therapeutics' return on equity.
Summary
Omega Therapeutics beats Karyopharm Therapeutics on 10 of the 18 factors compared between the two stocks.
Get Omega Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for OMGA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OMGA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Omega Therapeutics Competitors List
Related Companies and Tools
